DEALS: Bausch & Lomb expands China operations

Bausch & Lomb expands China operations
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Bausch & Lomb |
Sino Biopharmaceutical |
Buying 55% interest in Chinese ophthalmic unit |
Bausch & Lomb expands its presence in the Chinese market. |
|
Techne |
Fortron Bio Science/BiosPacific |
$20M buyout |
Techne gains a developer and manufacturer of monoclonal and polyclonal antibodies, antigens and other biological reagents. |
|
Qiagen |
Nextal Biotechnology |
$14.2M Buyout |
Qiagen gains a provider of proprietary sample preparation tools which make protein crystallization more accessible. |
|
Torrent Pharma |
Pfizer |
Generic division buyout |
India's Torrent acquires Heumann Pharma Generics of Germany for an undisclosed amount. |
|
Takara Bio |
Becton, Dickinson and Company |
Acquiring BD's Clontech division |
Clontech develops, produces and markets biological products to the life science market. |
|
Blairex Laboratories |
Zila |
Brand line sale, $10.3M |
Blairex gains the Zilactin brand of OTC lip and oral care products. |
|
Millipore |
Microsafe |
$9.3 million buyout |
Millipore adds contract lab to its list of assets. |
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


